Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized single-blind study of low-dose oral selinexor in severe COVID-19 infection
2020-001411-25Phase 2Completed
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in coronavirus disease 2019 (COVID-19) comparing Selinexor low-dose arm with Standard of care arm (2 arms). Primary endpoint: Time to Clinical Improvement (TTCI). Started Apr 2020; status: completed.
02
Drugs
selinexor
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001411-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001411-25.